CR20220160A - Derivados de piridazin-3(2h)-ona fusionados con azol - Google Patents

Derivados de piridazin-3(2h)-ona fusionados con azol

Info

Publication number
CR20220160A
CR20220160A CR20220160A CR20220160A CR20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A CR 20220160 A CR20220160 A CR 20220160A
Authority
CR
Costa Rica
Prior art keywords
pyridazin
azole
fused
derivatives
gpr139
Prior art date
Application number
CR20220160A
Other languages
English (en)
Inventor
Sean Murphy
Melinda Davis
Scott Olsen
Holly Reichard
Holger Monenschein
Natasha O'rourke
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20220160A publication Critical patent/CR20220160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se dan a conocer los compuestos de la fórmula 1 y las sales farmacéuticamente aceptables de los mismos, en donde a, ß, n, R4, R5, R6, R7, R8, R9, R10, R11, X1, X2, X3 y X7 se definen en la memoria descriptiva. Esta divulgación también se refiere a los materiales y métodos para la preparación los compuestos de la fórmula 1, a las composiciones farmacéuticas que comprenden los mismos, y a su uso para el tratamiento de las enfermedades, los trastornos y las afecciones asociadas con el GPR139.
CR20220160A 2019-09-16 2020-09-15 Derivados de piridazin-3(2h)-ona fusionados con azol CR20220160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901052P 2019-09-16 2019-09-16
PCT/US2020/050823 WO2021055326A1 (en) 2019-09-16 2020-09-15 Azole-fused pyridazin-3(2h)-one derivatives

Publications (1)

Publication Number Publication Date
CR20220160A true CR20220160A (es) 2022-06-16

Family

ID=72670806

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220160A CR20220160A (es) 2019-09-16 2020-09-15 Derivados de piridazin-3(2h)-ona fusionados con azol

Country Status (19)

Country Link
US (1) US20230028114A1 (es)
EP (1) EP4031552A1 (es)
JP (1) JP2022548602A (es)
KR (1) KR20220063228A (es)
CN (1) CN114728975A (es)
AR (1) AR119971A1 (es)
AU (1) AU2020348675A1 (es)
BR (1) BR112022004819A2 (es)
CA (1) CA3150508A1 (es)
CO (1) CO2022004684A2 (es)
CR (1) CR20220160A (es)
DO (1) DOP2022000057A (es)
EC (1) ECSP22020159A (es)
IL (1) IL291181A (es)
JO (1) JOP20220063A1 (es)
MX (1) MX2022003177A (es)
PE (1) PE20221341A1 (es)
TW (1) TW202124386A (es)
WO (1) WO2021055326A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114149371B (zh) * 2021-11-26 2023-08-22 首都医科大学 四取代吡唑类化合物及其应用
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN116063179A (zh) * 2023-02-20 2023-05-05 南京杰运医药科技有限公司 一种4-甲氧基乙酰乙酸甲酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20160022636A1 (en) 2013-03-14 2016-01-28 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
EP4031552A1 (en) 2022-07-27
CA3150508A1 (en) 2021-03-25
BR112022004819A2 (pt) 2022-06-07
TW202124386A (zh) 2021-07-01
ECSP22020159A (es) 2022-05-31
AR119971A1 (es) 2022-01-26
CO2022004684A2 (es) 2022-07-08
MX2022003177A (es) 2022-04-06
KR20220063228A (ko) 2022-05-17
WO2021055326A1 (en) 2021-03-25
PE20221341A1 (es) 2022-09-13
DOP2022000057A (es) 2022-06-30
IL291181A (en) 2022-05-01
AU2020348675A1 (en) 2022-04-14
JOP20220063A1 (ar) 2023-01-30
US20230028114A1 (en) 2023-01-26
CN114728975A (zh) 2022-07-08
JP2022548602A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2020007265A (es) Derivados de rapamicina.
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
PH12021550872A1 (en) Therapeutic compounds
CR20210544A (es) DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MY189372A (en) Indole derivatives